CD19 and non-Hodgkin lymphoma: In patients with R/R non-Hodgkin lymphoma (NHL), the long-term follow-up of Axicabtagene ciloleucel, an anti-CD19 CAR-T therapy, reported a median overall survival (OS) of 25.8 months [95% confidence interval (CI), 12.8–NE] (4), while the median OS was only 6.3 months (95% CI, 5.9–7.0) in R/R NHL patients (n = 636) treated with chemotherapies or autologous stem cell transplantation (5).